Healthy Volunteers
Conditions
Keywords
Pharmacokinetics, HGF/MET
Brief summary
This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of ATH-1020 in healthy young and elderly subjects.
Detailed description
This is a Phase 1 first-in-human, 2-part adaptive study. Both Part A and Part B will be performed in a randomized, placebo-controlled, and double-blind manner. Part A - Single Ascending Dose (SAD) Part A will be a SAD study investigating multiple dose levels of ATH 1020. Part B - Multiple Ascending Dose (MAD) Part B will be a multiple ascending dose (MAD) study investigating multiple dose levels of ATH-1020. Subjects in Cohort B5 (4 subjects) will additionally undergo CSF sampling pre-dose on Day 4 and up to 3 post dose timepoints to evaluate ATH-1020 blood-brain-barrier penetration
Interventions
DRUGATH-1020
ATH-1020 in oral capsule form
DRUGPlacebo
Placebo in oral capsule form
Sponsors
Biotrial Inc.
Alturas Analytics, Inc.
Athira Pharma
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
All Subjects 1. Body mass index (BMI) of ≥ 18.0 and ≤ 32.0 kg/m2 at Screening, with minimum weight of 60 kg. 2. Subjects in generally good health per the investigator's discretion. 3. Male subjects and their partners must be willing to comply with the contraceptive requirements of the study. 4. Subjects must have adequate venous access. Part A (SAD) 5. Male subjects aged 18 to 50 years at the time of signing the informed consent. Part B (MAD) 6. Male subjects aged 18 to 50 years (Cohorts B1, B2, B3, and B5); male and post-menopausal female subjects aged 65 to 85 years (Cohort B4) at the time of signing the informed consent.
Exclusion criteria
1. History of significant drug allergies (including to any excipients) or of anaphylactic reaction. 2. Any condition per the investigator's discretion, which while not requiring chronic medication use, is likely to require intermittent/acute therapeutic intervention. 3. Any history of seizures or loss of consciousness for an unknown reason. 4. History of or positive results of serology screening for hepatitis B, hepatitis C or human immunodeficiency virus (HIV). 5. Abnormal liver tests 6. Impaired renal function. 7. History of having taken another investigational drug within 30 days prior to Admission (Day -1). 8. Major surgery within 90 days prior to Admission (Day -1) or anticipated surgery during the study. Part A (SAD) 9. Female subjects are not permitted. 10. Any medical condition that requires chronic medication use. Part B (MAD) 11. A history of intermittent benzodiazepine (short-acting only) or other treatments for insomnia and anxiety are allowed, provided that the subject is able to abstain from their use during the Screening period, and from Admission until discharge from the study. 12. Reported changes in cognition and reported history of declines in everyday life in the last year. Part B (MAD) CSF Sampling (Cohort B5) 13. Subject history of or current contraindication to lumbar puncture/spinal catheterization. 14. Clinically significant abnormalities in coagulation parameters.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) | Up to 12 days post initial dosing (Part A); Up to 19 days post initial dosing (Part B) | Safety and tolerability of single or multiple ascending doses of ATH-1020 as measured by vital signs and clinical laboratory measurements. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to maximum observed plasma concentration (Tmax) | Samples collected pre-dose and at predetermined timepoints within 48 hours post-dose. | Tmax will be determined from all collected plasma samples from baseline through up to 48 hours post-dose. |
| Plasma concentration at the end of the dosing interval (Ctrough) | Samples collected pre-dose and at predetermined timepoints within 24 hours post-dose. | Ctrough will be determined from the last plasma sample prior to the following dose (cohort B only). |
| Maximum observed plasma concentration (Cmax) | Cmax will be determined from all collected plasma samples from baseline through up to 48 hours post-dose. | Cmax will be determined from all collected plasma samples from baseline through up to 48 hours post-dose. |
| Half-life (t1/2) | Samples collected pre-dose and at predetermined timepoints within 48 hours post-dose. | t1/2 will be determined from all collected plasma samples from baseline through up to 48 hours post-dose. |
| Amount of IMP excreted unchanged in the urine (Ae) | Samples collected pre-dose on Day 1 and predetermined timepoints on Day 1, 9, and 10, within 24 hours post-dose. | Ae will be determined from all collected urine samples from baseline through up to 24 hours post-dose (cohort B1-4 only). |
| Area under the plasma concentration time curve (AUC) | Samples collected pre-dose and at predetermined timepoints within 48 hours post-dose. | AUC will be determined from all collected plasma samples from baseline through up to 48 hours post-dose. |
Countries
United States
Outcome results
None listed